Currently, there is a pharmacological ACAA2 inhibitor, trimetazidine hydrochloride, that is currently used to treat angina pectoris and myocardial ischaemia as an anti-ischaemic (anti-anginal) metabolic agent in Europe [47]. This evidence concerns the gene ACAA2 and angina pectoris.